diffuse large B-cell lymphoma

HCRU, Costs With CAR-T Therapy Compared to Transplantation for DLBCL
Videos
HCRU, Costs With CAR-T Therapy Compared to Transplantation for DLBCL
12/17/2020
Karl Kilgore, PhD, discusses study results that showed greater HCRU and costs with CAR-T therapy than transplantation for patients with relapsed/refractory DLBCL.
Karl Kilgore, PhD, discusses study results that showed greater HCRU and costs with CAR-T therapy than transplantation for patients with relapsed/refractory DLBCL.
Karl Kilgore, PhD, discusses...
12/17/2020
Journal of Clinical Pathways
Conference Coverage
Comparison of HCRU and Costs Associated With Treatments for Relapsed/Refractory DLBCL
12/06/2020
HCRU and costs associated with CAR-T therapy were greater than transplantation for DLBCL and cost offsets before and after the procedures provide useful insight for treatment planning.
HCRU and costs associated with CAR-T therapy were greater than transplantation for DLBCL and cost offsets before and after the procedures provide useful insight for treatment planning.
HCRU and costs associated with...
12/06/2020
Journal of Clinical Pathways
NCCN B-Cell Lymphomas Guideline Features Therapy Updates in Follicular Lymphoma, DLBCL
Guideline Updates
NCCN B-Cell Lymphomas Guideline Features Therapy Updates in Follicular Lymphoma, DLBCL
07/13/2020
The National Comprehensive Cancer Network (NCCN) released an update to its guideline for B-cell lymphomas. In the section for follicular lymphoma with histologic transformation to diffuse large B-cell lymphoma...
The National Comprehensive Cancer Network (NCCN) released an update to its guideline for B-cell lymphomas. In the section for follicular lymphoma with histologic transformation to diffuse large B-cell lymphoma...
The...
07/13/2020
Journal of Clinical Pathways
News
Identifying Biomarkers for Relapsed, Refractory DLBCL Subtype
06/16/2020
A study presented at the European Hematology Association (EHA) Virtual Meeting (June 11-21, 2020) sought to identify biomarkers in patients with relapsed or refractory non-germinal center B-cell-like (non-GCB)...
A study presented at the European Hematology Association (EHA) Virtual Meeting (June 11-21, 2020) sought to identify biomarkers in patients with relapsed or refractory non-germinal center B-cell-like (non-GCB)...
A...
06/16/2020
Journal of Clinical Pathways
News
Hypercalcemia as a Biomarker for Aggressive Disease in Patients With B-Cell Lymphoma
05/13/2020
For patients with diffuse large B-cell lymphoma (DLBCL), presence of hypercalcemia at diagnosis correlates with negative prognostic factors and a short diagnosis-to-treatment interval, according to a retrospective...
For patients with diffuse large B-cell lymphoma (DLBCL), presence of hypercalcemia at diagnosis correlates with negative prognostic factors and a short diagnosis-to-treatment interval, according to a retrospective...
For...
05/13/2020
Journal of Clinical Pathways
Research in Review
Comparative Effectiveness Study Examines Treatment Options for DLBCL
08/18/2017
JCP Editors
A recent study compared the treatment effects and adverse events of first-line chemotherapy regimens in patients with treatment-naïve diffuse large B-cell lymphoma (DLBCL). Rituximab plus cyclophosphamide,...
A recent study compared the treatment effects and adverse events of first-line chemotherapy regimens in patients with treatment-naïve diffuse large B-cell lymphoma (DLBCL). Rituximab plus cyclophosphamide,...
A...
08/18/2017
Journal of Clinical Pathways
Research in Review
Immunotherapy Better Than Standard of Care for Type of DLBCL
08/03/2017
JCP Editors
Single-agent immunotherapy in patients with a subtype of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) provides more clinical benefit than conventional therapy, according to research published in...
Single-agent immunotherapy in patients with a subtype of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) provides more clinical benefit than conventional therapy, according to research published in...
...
08/03/2017
Journal of Clinical Pathways
Research in Review
Prognostic Indicator Identified for Patients With DLBCL
07/14/2017
JCP Editors
Patients with diffuse large B-cell lymphoma (DLBCL) with a specific disease characteristic are expected to have poor clinical outcomes, according to research published in Leukemia (published online July 12, 2017;...
Patients with diffuse large B-cell lymphoma (DLBCL) with a specific disease characteristic are expected to have poor clinical outcomes, according to research published in Leukemia (published online July 12, 2017;...
...
07/14/2017
Journal of Clinical Pathways
Research in Review
Does Intensified Therapy Improve Prognosis in DLBCL?
07/03/2017
JCP Editors
Recent research compared the effects of standard chemotherapy dosage with intensified chemotherapy for patients with high-risk diffuse large B-cell lymphoma (DLBCL), published in The Lancet Oncology (published online...
Recent research compared the effects of standard chemotherapy dosage with intensified chemotherapy for patients with high-risk diffuse large B-cell lymphoma (DLBCL), published in The Lancet Oncology (published online...
Recent...
07/03/2017
Journal of Clinical Pathways
Research in Review
Intensified Regimens More Effective Than Standard Therapy in DLBCL
06/28/2017
JCP Editors
Intensified regimens improve event-free survival (EFS) and overall survival (OS) in patients newly diagnosed with diffuse large B-cell lymphoma (DLBCL) compared with standard therapy, according to research presented...
Intensified regimens improve event-free survival (EFS) and overall survival (OS) in patients newly diagnosed with diffuse large B-cell lymphoma (DLBCL) compared with standard therapy, according to research presented...
...
06/28/2017
Journal of Clinical Pathways

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use